Tango Therapeutics (Tango Therapeutics) Cash-to-Debt : 8.66 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tango Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.66.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tango Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Tango Therapeutics's Cash-to-Debt or its related term are showing as below:

TNGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.66 Med: 16.52 Max: 322.86
Current: 8.66

During the past 4 years, Tango Therapeutics's highest Cash to Debt Ratio was 322.86. The lowest was 8.66. And the median was 16.52.

TNGX's Cash-to-Debt is ranked better than
53.54% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs TNGX: 8.66

Tango Therapeutics Cash-to-Debt Historical Data

The historical data trend for Tango Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tango Therapeutics Cash-to-Debt Chart

Tango Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

24.14

322.86

8.90

8.66

Tango Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial									8.90	8.06	7.79	9.11	8.66

Competitive Comparison of Tango Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Tango Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tango Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tango Therapeutics's Cash-to-Debt falls into.

Tango Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tango Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	336.885	/	(2.082	+	36.838)
	=	8.66

Tango Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	336.885	/	(2.082	+	36.838)
	=	8.66

Tango Therapeutics (NAS:TNGX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tango Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tango Therapeutics (Tango Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215

Website

https://www.tangotx.com

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.

Executives

Adam Crystal	officer: See Remarks	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
John B Ketchum	director	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc	director	201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p.	director	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p.	director	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron Weitzman	officer: Chief Medical Officer	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Marc Rudoltz	officer: Chief Medical Officer	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Douglas Barry	officer: See Remarks	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116